title: Oral nicotinamide and actinic keratosis: a supplement success story.
abstract: Nicotinamide has shown potential as a safe and effective intervention for the prevention of malignant and premalignant skin lesions. Recent studies have shown that nicotinamide, in both oral and topical forms, is able to prevent ultraviolet-induced immunosuppression in humans [1,2,3] and mice [4,5]. Immunosuppression is a known factor for the progression of premalignant lesions, such as actinic keratosis [6]. Murine studies have shown that nicotinamide is also able to protect against photocarcinogenesis [4,5]. Preliminary human studies suggest that nicotinamide may help prevent skin cancers and enhance the regression of actinic keratoses.
authors.affiliation: Dermatology Research Laboratories, Bosch Institute, The University of Sydney, Sydney, N.S.W., Australia.
authors.forename: Burcu
authors.initials: B
authors.lastname: Kim
authors.forename: Gary M
authors.initials: GM
authors.lastname: Halliday
authors.forename: Diona L
authors.initials: DL
authors.lastname: Damian
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D004260:DNA Repair / Q000187:drug effects; D019587:Dietary Supplements; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D055623:Keratosis, Actinic / Q000188:drug therapy*; D051379:Mice; D009536:Niacinamide / Q000008:administration & dosage*; D012878:Skin Neoplasms / Q000517:prevention & control; D014466:Ultraviolet Rays
chemical_list: D000970:Antineoplastic Agents; D009536:Niacinamide